coronaviru
diseas
sever
acut
respiratori
syndrom
sar
characteris
overexuber
inflammatori
respons
sar
viral
load
correl
worsen
symptom
previou
correspond
lancet
describ
benevolentai
proprietari
artifici
intellig
ai
deriv
knowledg
graph
queri
suit
algorithm
enabl
identif
target
potenti
therapeut
sar
coronaviru
caus
organ
identifi
group
approv
drug
could
inhibit
clathrinmedi
endocytosi
therebi
inhibit
viral
infect
cell
appendix
drug
target
member
numbassoci
kinas
nak
familyinclud
gakth
inhibit
shown
reduc
viral
infect
vitro
baricitinib
identifi
nak
inhibitor
particularli
high
affin
pivot
regul
clathrinmedi
endocytosi
suggest
drug
could
use
counter
infect
subject
appropri
clinic
test
take
work
short
timescal
necess
deal
new
human
pathogen
reexamin
affin
select
approv
drug
knowledg
graph
identifi
antivir
antiinflammatori
properti
drug
predict
particular
import
treatment
sever
case
host
inflammatori
respons
becom
major
caus
lung
damag
subsequ
mortal
comparison
properti
three
best
candid
shown
tabl
baricitinib
fedratinib
ruxolitinib
potent
select
jak
inhibitor
approv
indic
rheumatoid
arthriti
myelofibrosi
three
power
antiinflammatori
jakstat
signal
inhibitor
like
effect
consequ
elev
level
cytokin
includ
typic
observ
peopl
although
three
candid
similar
jak
inhibitor
potenc
high
affin
suggest
baricitinib
best
group
especi
given
oncedaili
oral
dose
accept
sideeffect
profil
signific
sideeffect
seen
patientyear
clinic
trial
programm
use
european
medicin
agenc
registr
small
increas
upper
respiratori
tract
infect
similar
observ
methotrex
incid
seriou
infect
eg
herp
zoster
week
dose
small
per
patientyear
similar
placebo
use
agent
patient
day
exampl
suggest
sideeffect
would
trivial
aialgorithmpredict
nak
inhibitor
includ
combin
oncolog
drug
sunitinib
erlotinib
shown
reduc
infect
wide
rang
virus
includ
hepat
c
viru
dengu
viru
ebola
viru
respiratori
syncyti
viru
howev
sunitinib
erlotinib
would
difficult
patient
toler
dose
requir
inhibit
gak
contrast
therapeut
dose
use
treatment
patient
rheumatoid
arthriti
free
plasma
concentr
baricitinib
predict
suffici
inhibit
potenti
gak
cellbas
assay
predict
inhibit
clathrinmedi
endo
cytosi
baricitinib
unlik
observ
antiarthrit
drug
jak
inhibitor
analysi
close
relat
jak
inhibitor
ruxolitinib
fedratinib
tabl
illustr
predict
unbound
plasma
exposur
requir
inhibit
enzym
need
clathrinmedi
endocytosi
greatli
exce
current
toler
exposur
use
therapeut
drug
therefor
unlik
reduc
viral
infect
toler
dose
although
might
reduc
host
inflammatori
respons
jak
inhibit
intriguingli
anoth
jak
inhibitor
tofacitinib
show
detect
inhibit
high
affin
baricitinib
nak
antiinflammatori
properti
abil
amelior
associ
chronic
infla
mmation
interferonopathi
togeth
advantag
pharmacokinet
properti
appear
make
special
case
among
approv
drug
addit
potenti
combin
therapi
baracitinib
high
low
plasma
protein
bind
minim
interact
cyp
enzym
drug
transport
furthermor
potenti
combin
baricitinib
directact
antivir
lopinavir
ritonavir
remdesivir
current
use
outbreak
sinc
minim
interact
relev
cyp
drugmetabolis
enzym
combin
baricitinib
directact
antivir
could
reduc
viral
infect
viral
replic
aberr
host
inflammatori
respons
work
demonstr
use
aidriven
knowledg
graph
facilit
rapid
drug
develop
js
editorinchief
oncogen
js
previous
sat
number
scientif
advisori
board
includ
benevolentai
consult
lansdown
partner
vitruvian
sit
board
director
bb
biotech
healthcar
trust
chair
xerion
healthcar
author
employe
benevolentai
event
relat
outbreak
evolv
rapidli
make
initi
thought
avail
comment
good
faith
assist
global
respons
earli
investig
suggest
requir
detail
work
analysi
reli
constitut
kind
medic
advic
recommend
